8-K filings / November 20, 2026
60 DEGREES PHARMACEUTICALS, INC.: A stock exchange listing notice
60 DEGREES PHARMACEUTICALS, INC. filed a current report (Form 8-K) with the SEC on November 20, 2026. It reports a stock exchange listing notice.
Item 3.01
Stock exchange listing notice
-
Exchange
Nasdaq
From the filing
Source
“On November 19, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the bid price of the Company’s listed securities had closed at less than $1.00 per share over the previous 30 consecutive business days, from October 8, 2026 through November 18, 2026, and, as a result, the Company did not comply with the minimum bid price requirement for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).”
Read by code from this sentence of the filing. -
What it says
A decision to delist, or a step in the hearing on it
From the filing
Source
“Accordingly, Staff has determined to delist the Company’s securities from The Nasdaq Capital Market.”
Read by code from this sentence of the filing. -
Rule cited
Nasdaq Listing Rule 5550(a)(2)
From the filing
Source
“On November 19, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the bid price of the Company’s listed securities had closed at less than $1.00 per share over the previous 30 consecutive business days, from October 8, 2026 through November 18, 2026, and, as a result, the Company did not comply with the minimum bid price requirement for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).”
Read by code from this sentence of the filing. -
Notice date
November 19, 2026
From the filing
Source
“On November 19, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the bid price of the Company’s listed securities had closed at less than $1.00 per share over the previous 30 consecutive business days, from October 8, 2026 through November 18, 2026, and, as a result, the Company did not comply with the minimum bid price requirement for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).”
Read by code from this sentence of the filing.
Not investment advice.Read the filing on SEC.gov
Facts read from the filing's own text; a fact the filing does not state clearly is left out. All documents of this filing on SEC.gov.